Loading...
•
Dec 31, 2024
Dyne Therapeutics Q4 2024 Earnings Report
Reported financial results for the fourth quarter and full year 2024 and recent business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $89.5 million for Q4 2024. The company's cash, cash equivalents, and marketable securities totaled $642.3 million as of December 31, 2024, which, combined with proceeds from a Q1 2025 stock sale, is expected to fund operations into the second half of 2026.
Received FDA Fast Track Designation for DYNE-101 in DM1.
Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 planned for mid-2025 to support submission for U.S. Accelerated Approval.
Full Enrollment of Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD planned for Q1 2025 to support submission for U.S. Accelerated Approval.
Cash, cash equivalents and marketable securities were $642.3 million as of December 31, 2024.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates a potential submission for U.S. Accelerated Approval for DYNE-101 in H1 2026 and for DYNE-251 in early 2026.